share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

諾瓦瓦克斯醫藥 | SC 13G/A:超過5%持股股東披露文件(修正)-The Vanguard Group(9.63%)
美股SEC公告 ·  11/13 05:50

Moomoo AI 已提取核心訊息

The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a 9.63% ownership stake in Novavax Inc. This filing, which reflects the state of ownership as of September 30, 2024, reports that The Vanguard Group has beneficial ownership of 15,430,034 shares of Novavax's common stock. The group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Novavax and were not held in connection with any transaction having that purpose or effect.
The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a 9.63% ownership stake in Novavax Inc. This filing, which reflects the state of ownership as of September 30, 2024, reports that The Vanguard Group has beneficial ownership of 15,430,034 shares of Novavax's common stock. The group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Novavax and were not held in connection with any transaction having that purpose or effect.
The Vanguard Group已於2024年11月12日向證券交易委員會提交了修訂後的13G表格,表明其持有諾瓦瓦克斯醫藥公司9.63%的股權。該申報反映了2024年9月30日的股權狀況,報告稱The Vanguard Group擁有諾瓦瓦克斯醫藥普通股15,430,034股的受益所有權。該團體對224,741股股票擁有共同表決權,並對15,072,218股股票擁有獨立處分權,另有357,816股股票的共同處分權。申報聲稱這些股票不是爲改變或影響諾瓦瓦克斯醫藥公司的控制目的而收購,並且不是爲進行具有該目的或效果的交易而持有的。
The Vanguard Group已於2024年11月12日向證券交易委員會提交了修訂後的13G表格,表明其持有諾瓦瓦克斯醫藥公司9.63%的股權。該申報反映了2024年9月30日的股權狀況,報告稱The Vanguard Group擁有諾瓦瓦克斯醫藥普通股15,430,034股的受益所有權。該團體對224,741股股票擁有共同表決權,並對15,072,218股股票擁有獨立處分權,另有357,816股股票的共同處分權。申報聲稱這些股票不是爲改變或影響諾瓦瓦克斯醫藥公司的控制目的而收購,並且不是爲進行具有該目的或效果的交易而持有的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息